knowledge -WSS

knowledge

author：fashion 2025-09-28 00:25:51 - browse：54

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： NEJM study measures Covid brain fog, impact on IQ

WSS

Color Health wants to make cancer screenings convenient

Laying a path for careers in science

Are embryos people? Reproductive medicine's future depends on the answer

Study fuels hope CAR

Study fuels hope CAR

Microbiome research is starting to find links to chronic diseases

Wikipedia

knowledge

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

It's been 20 years since Dolly the sheep. Where's my clone?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Senate HELP committee spars over health care workforce policies

Continuity nursing helped my family in our darkest PICU moments

Change Healthcare cyberattack shows risk of industry consolidation

Activists slam private health insurers over coverage restrictions

CDC advisory group OKs chikungunya vaccine

Virginia high school admissions case could be legal follow

Readout Newsletter: Beam, Prozac, "TechBio" and more

explore

Are embryos people? Reproductive medicine's future depends on the answer

Biotech lab space demand falls sharply

CDC advisers recommend seasonal use of Pfizer RSV shot

Laying a path for careers in science

What Congress can do to address the rural doctor shortage

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

hotspot

knowledge

knowledge

hotspot